Imino Sugars Are Potent Agonists of the Human Glucose Sensor SGLT3
- 16 November 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 71 (2), 628-634
- https://doi.org/10.1124/mol.106.030288
Abstract
Imino sugars are used to treat type 2 diabetes mellitus [miglitol (Glyset)] and lysosomal storage disorders [miglustat (Zavesca)] based on the inhibition of α-glucosidases and glucosyltransferases. In this substrate specificity study, we examined the interactions of imino sugars with a novel human glucose sensor, sodium/glucose cotransporter type 3 (hSGLT3), using expression in Xenopus laevis oocytes and electrophysiology. The results for hSGLT3 are compared with those for α-glucosidases and human SGLT type 1 (hSGLT1), a well characterized sodium/glucose cotransporter of the SGLT family. In general, substrates have lower apparent affinities (K0.5) for hSGLT3 than hSGLT1 (d-glucose, α-methyl-d-glucose, 1-deoxy-d-glucose, and 4-deoxy-4-fluoro-d-glucose exhibit K0.5 values of 19, 21, 43, and 17 mM, respectively, for hSGLT3, and 0.5, 0.7, 10, and 0.07 mM, respectively, for hSGLT1). However, specificity of hSGLT3 binding is greater (d-galactose and 4-deoxy-4-fluoro-d-galactose are not hSGLT3 substrates, but have hSGLT1 K0.5 values of 0.6 and 1.3 mM). An important deviation from this trend is potent hSGLT3 activation by the imino sugars 1-deoxynojirimycin (DNJ), N-hydroxylethyl-1-deoxynojirimycin (miglitol), N-butyl-1-deoxynojirimycin (miglustat), N-ethyl-1-deoxynojirimycin, and 1-deoxynojirimycin-1-sulfonic acid, with K0.5 values of 0.5 to 9 μM. The diastereomer 1-deoxygalactonojirimycin activates hSGT3 with a K0.5 value of 11 mM, a 3000-fold less potent interaction than is observed for DNJ (4 μM). These imino sugar binding characteristics are similar to those for α-glucosidases, but there are no interactions with hSGLT1. This work provides insights into hSGLT3 and -1 substrate binding interactions, establishes a pharmacological profile to study endogenous hSGLT3, and may have important ramifications for the clinical application of imino sugars.This publication has 33 references indexed in Scilit:
- Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher diseaseJournal of Inherited Metabolic Disease, 2004
- Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff diseaseNeurobiology of Disease, 2004
- The Polar Hydrophobicity of Fluorinated CompoundsChemBioChem, 2004
- Organic Fluorine: Odd Man OutChemBioChem, 2004
- A glucose sensor hiding in a family of transportersProceedings of the National Academy of Sciences of the United States of America, 2003
- Structure and Mechanism of the Lactose Permease of Escherichia coliScience, 2003
- Glycosidase inhibitors: update and perspectives on practical useGlycobiology, 2003
- Residue 457 Controls Sugar Binding and Transport in the Na+/Glucose CotransporterJournal of Biological Chemistry, 2001
- Glycoside Binding and Translocation in Na + -Dependent Glucose Cotransporters: Comparison of SGLT1 and SGLT3The Journal of Membrane Biology, 2000
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000